Molecular Partners AG (MOLN)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
| Previous close | 6.73 |
| Open | 6.81 |
| Bid | 6.80 x 900 |
| Ask | 6.98 x 900 |
| Day's range | 6.75 - 6.94 |
| 52-week range | 5.92 - 32.04 |
| Volume | |
| Avg. volume | 29,916 |
| Market cap | 228.101M |
| Beta (5Y monthly) | 0.68 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.43 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 33.11 |
- Motley Fool
3 Stocks That Have Soared as the Market Sank: Are They Buys Now?
It's hard for any stock to deliver positive gains while the market is falling. Molecular Partners' (NASDAQ: MOLN) shares have skyrocketed more than 40% year to date. On Jan. 10, Molecular Partners and Novartis announced positive results from their Empathy phase 2 study of ensovibep in treating acute COVID-19 patients.
- Motley Fool
Novartis Hopes to Have Another COVID Therapy on the Way
Novartis and Molecular Partners reported positive results for COVID-19 candidate ensovibep.
- Zacks
Biotech Stock Roundup: BIIB's AD Drug Update, AMGN's Drug Approval & Other Updates
Regulatory and other pipeline updates from Biogen (BIIB) and AMGN are among a few key highlights from the biotech sector during the past week.
© 2022 Yahoo. All rights reserved.
